Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVRL1 | P37023 | 11/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | GALR3 | O60755 | 1/20 | 0.34 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.34 |
| ▸ | CSNK2A2 | P19784 | 5/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 5/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10105829 | 0.89 | ACVRL1 (0.39) | ACVRL1CSNK2A2CSNK2A1PIK3CD | |
| SCHEMBL10105828 | 0.87 | ACVRL1 (0.39) | ACVRL1CSNK2A2CSNK2A1TNK2PIK3CD | |
| SCHEMBL14642544 | 0.83 | ACVRL1 (0.41) | ACVRL1CSNK2A2CSNK2A1CYP2A6TNK2 | |
| SCHEMBL26944060 | 0.83 | ACVRL1 (0.43) | ACVRL1CYP2A6TNK2PIK3CD | |
| SCHEMBL7605058 | 0.83 | ACVRL1 (0.44) | ACVRL1PIK3CD | |
| SCHEMBL7602181 | 0.80 | PIK3CD (0.42) | ACVRL1PIK3CD | |
| SCHEMBL7602186 | 0.80 | ACVRL1 (0.36) | ACVRL1NPC1GALR3S1PR4ALDH1A1 | |
| SCHEMBL7602863 | 0.77 | ACVRL1 (0.43) | ACVRL1PIK3CD | |
| SCHEMBL14642736 | 0.76 | ACVRL1 (0.45) | ACVRL1PIK3CD | |
| SCHEMBL26195756 | 0.76 | CYP2A6 (0.37) | ACVRL1ALDH1A1CYP2A6TNK2PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122811-A1 | BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122811-A1 | BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS | NTPCR, PNP, DCTD | ACVRL1 4215/4885NPC1 1041/4885GALR3 4629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.